The company’s management will first present at the Align Summit in Boston on October 15, focusing on its advancements in protein therapeutics. Following this, the team will join a panel discussion at the BioFuture conference in New York on October 28 to discuss the broader landscape of biopharma breakthroughs. These appearances serve as a platform for the firm to engage with investors regarding its clinical strategy and upcoming milestones.
In section Releases
Consano Bio Previews C-1101 Data for Chronic Sciatica Treatment
Burlington-based Consano Bio is taking its lead clinical candidate, C-1101, to the industry stage this month. The biotechnology firm plans to showcase its novel, platelet-derived biologic for chronic lumbosacral radiculopathy at two major East Coast forums, aiming to secure new partnerships and outline its development roadmap.
C-1101 represents a potential first-in-class treatment for chronic sciatica, a condition currently lacking FDA-approved pharmaceutical options. By delivering a concentrated mix of cytokines, growth factors, and matrix proteins directly to injured spinal nerve roots via epidural injection, the therapy aims to trigger localized cellular repair. As Consano Bio refines its approach to addressing the underlying inflammation of lumbosacral radiculopathy, these conference sessions will provide the latest insight into the company's efforts to move the candidate through clinical development.
Comments (0)
No comments yet. Be the first!